44. Wegener granulomatosis Clinical trials / Disease details


Clinical trials : 98 Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-003903-21-FR
(EUCTR)
04/06/201919/02/2019A Study to Assess the pharmacokinetics and pharmacodynamics of INS1007 Administered Once Daily in Patients with Granulomatosis with Polyangiitis (GPA)A Randomized, Single-Blind Study to Evaluate the Pharmacokinetics (PK), and Pharmacodynamics (PD) of INS1007 Administered for 12 Weeks in Subjects with Granulomatosis with Polyangiitis (GPA) Granulomatosis with Polyangiitis (GPA
MedDRA version: 20.0;Level: PT;Classification code 10072579;Term: Granulomatosis with polyangiitis;System Organ Class: 10047065 - Vascular disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: INS1007
INN or Proposed INN: Not available
Other descriptive name: AZD7986
Product Name: INS1007
INN or Proposed INN: Not available
Other descriptive name: AZD7986
Product Name: INS1007
INN or Proposed INN: Not available
Other descriptive name: AZD7986
Insmed IncorporatedNULLNot Recruiting Female: yes
Male: yes
16 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noFrance